Clinical Research Directory

Inclusion Criteria: Screening Phase: * English or Spanish-proficient men and women aged ≥18 years * Histological diagnoses of invasive carcinoma of the breast * Plan to receive curative intent chemotherapy regimen containing 12 weeks weekly paclitaxel or nab-paclitaxel as standard of care Intervention Phase: * TIPN grade ≥1 based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, developed while receiving taxane * ≥ 4 4 weeks of either weekly paclitaxel or nab-paclitaxel, or paclitaxel or abraxane with dosing every 2-3 weeks planned, as standard of care and at treating physician's discretion * Willing to adhere to requirement that no new pain medication or dose changes be taken throughout the first 12 weeks of the study period * Willing to adhere to all study-related procedures, including randomization to one of the two possible acupuncture treatments Exclusion Criteria: Screening Phase: * Pre-existing peripheral neuropathy within 28 days of screening consent * Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine or glutamine Intervention Phase: * Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine or glutamine * Use of acupuncture for symptom management within 28 days of intervention consent